Skip to main content
Article thumbnail
Location of Repository

Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season

By Adam Meijer, Angie Lackenby, Olav Hungnes, Bruno Lina, Sylvie van der Werf, Brunhilde Schweiger, Matthias Opp, John Paget, Jan van de Kassteele, Alan Hay and Maria Zambon


A high level of virus circulation and introduction of an antigenic drift variant in a susceptible population contributed to the spread of resistant virus

Topics: Research
Publisher: Centers for Disease Control and Prevention
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (2008). a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing;
    2. Complications of infl uenza and benefi ts of vaccination.
    3. (2007). Data analysis using regression and multilevel/hierarchical models. Cambridge:
    4. Detection of infl uenza viruses resistant to neuraminidase inhibitors in global surveillance during the fi rst 3 years of their use. Antimicrob Agents Chemother.
    5. (2000). Development of a sensitive chemiluminescent neuraminidase assay for the determination of infl uenza virus susceptibility to zanamivir. Anal Biochem.
    6. (2008). Emergence of resistance to oseltamivir among infl uenza A(H1N1) viruses in Europe. Euro Surveill
    7. (2008). Enzymatic properties of the neuraminidase of seasonal H1N1 infl uenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog.
    8. (2007). European Infl uenza Surveillance Scheme (EISS). Epidemiological and virological assessment of infl uenza activity in Europe during the winter 2005–2006. Euro Surveill.
    9. (2008). Fatal oseltamivirresistant infl uenza virus infection.
    10. (1979). Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem.
    11. (2009). Groupe Régional d’Observation de la Grippe and European Infl uenza Surveillance Scheme. Surveillance and impact of infl uenza
    12. (2007). Infl uenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season [letter]. Euro Surveill.
    13. (2007). Infl uenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. Euro Surveill.
    14. (2007). Infl uenza Drug Resistance Surveillance Team, National Institute of Infectious Diseases, Tokyo. Detection of oseltamivir-resistant infl uenza A/H1N1 virus strains with an H275Y mutation in Japan,
    15. (2007). Infl uenza virus susceptibility and resistance to oseltamivir. Antivir Ther.
    16. Infl uenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
    17. (2008). Infl uenza viruses with reduced sensitivity to the neuraminidase inhibitor drugs in untreated young children. Commun Dis Intell.
    18. (2008). Informatics assisting infl uenza antiviral susceptibility monitoring
    19. Managing infl uenza: amantadine, rimantadine and beyond.
    20. Methods for sentinel virological surveillance of infl uenza
    21. (2006). Models for discrete longitudinal data. 2nd ed. Springer series in statistics.
    22. (2007). Monitoring of neuraminidase inhibitor resistance among clinical infl uenza virus isolates in Japan during the 2003–2006 infl uenza seasons. Wkly Epidemiol Rec.
    23. (2005). Neuraminidase Inhibitor Susceptibility Network. Use of infl uenza antivirals during 2003–2004 and monitoring of neuraminidase inhibitor resistance. Wkly Epidemiol Rec.
    24. (2007). Neuraminidase inhibitor–resistant recombinant A/Vietnam/1203/04 (H5N1) infl uenza viruses retain their replication effi ciency and pathogenicity in vitro and in
    25. (2003). Neuraminidase sequence analysis and susceptibilities of infl uenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother.
    26. (2007). Organization. Infl uenza A(H1N1) virus resistance to oseltamivir. Last quarter
    27. (2008). Organization. Infl uenza A(H1N1) virus resistance to oseltamivir. Summary table [cited
    28. Oseltamivir (Tamifl u) and its potential for use in the event of an infl uenza pandemic. J Antimicrob Chemother.
    29. (2008). Rapid quantitation of neuraminidase inhibitor drug resistance in infl uenza virus quasispecies. Antivir Ther.
    30. Resistant infl uenza A viruses in children treated with oseltamivir: descriptive study.
    31. (2008). Surveillance for neuraminidase inhibitor resistance among human infl uenza A and B viruses circulating worldwide in 2004–2008. Antimicrob Agents Chemother.
    32. The evolution of infl uenza surveillance in Europe and prospects for the next ten years.
    33. The global impact of infl uenza on morbidity and mortality.
    34. The H274Y mutation in the infl uenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res.
    35. (2007). The war against infl uenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov.
    36. Virology Working Group of the European Infl uenza Surveillance Scheme. Implementation of the Community Network of Reference Laboratories for Human Infl uenza in Europe.
    37. Visual presentation of data by means of box plots.
    38. (2008). Widespread oseltamivir resistance in infl uenza A viruses (H1N1), South Africa. Emerg Infect Dis.
    39. (2007). World Infl uenza Centre. Characteristics of human infl uenza AH1N1, AH3N2, and B viruses isolated

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.